# Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

> **NCT00612859** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 217 (actual)

## Conditions studied

- Anxiety Disorders

## Interventions

- **DRUG:** levetiracetam

## Key facts

- **NCT ID:** NCT00612859
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612859, "Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00612859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*